Implications of the 5th Edition of the World Health Organization Classification and International Consensus Classification of Myeloid Neoplasm in Myelodysplastic Syndrome With Excess Blasts and Acute Myeloid Leukemia

• DOI: 10.3343/alm.2023.43.5.503
• Publication Date: 2023-04-21T01:36:37Z
• Authors: Cheonghwa Lee; Ha Nui Kim; Jung Ah Kwon; Soo-Young Yoon; Min Ji Jeon; Eun Sang Yu; Dae Sik Kim; Chul Won Choi; Jung Yoon
• Keywords: Leukemia, Myeloid, Acute; Consensus; Myeloproliferative Disorders; Myelodysplastic Syndromes; Mutation; Humans; Brief Communications; World Health Organization

The fifth edition of the WHO classification (2022 WHO) and International Consensus Classification ICC) myeloid neoplasms have been recently published. We reviewed changes in diagnosis distribution patients with MDS excess blasts (MDS-EB) or AML using both classifications. Forty-seven previously diagnosed as having MDS-EB available mutation analysis data, including targeted next-generation RNA-sequencing were included. reclassified 15 (31.9%) 27 (57.4%) based on 2022 ICC, respectively. One patient was a translocation categorized rare recurring Reclassification mostly due to addition mutation-based diagnostic criteria (i.e., AML, myelodysplasia-related) new entity associated